Transitioning From Vial To Prefilled Syringe: How Formulation Development Affects Manufacturing

By Natasha Van Rutten, Product Development Director, Catalent Biologics

Due to advances in technology and increased development of parenteral drugs, one of the fastest growing choices for drug delivery in the pharmaceutical industry is the prefilled syringe (PFS).¹ Not only can PFSs help cut manufacturing and product costs for pharmaceutical companies, but they also offer significant benefits to the physician and patient. However, before taking advantage of these benefits, it is important to understand how formulation development for a PFS affects manufacturing. Doing so can drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care.